默克雪兰诺有限公司

What 默克雪兰诺有限公司 does

默克雪兰诺有限公司 is the Chinese operating subsidiary of Merck KGaA, Darmstadt, Germany, a German science and technology company founded in 1668 and headquartered in Darmstadt. The Chinese entity is registered in Beijing and operates as part of Merck KGaA's Healthcare business unit (branded as EMD Serono in the US/Canada and Merck Serono elsewhere), focusing on pharmaceutical therapies across oncology, neurology and immunology, fertility, and general medicine (cardiovascular, metabolism, endocrinology). Merck KGaA as a group operates three integrated business sectors: Life Science (branded MilliporeSigma), Healthcare, and Electronics (branded EMD Electronics), with global reach across 65 countries and 62,000+ employees.

The group's underlying technology portfolio includes the mRNA platform for vaccines and therapies, proprietary AI platforms AIDDISON™ (AI-powered drug design producing makeable molecules) and Synthia (AI tool predicting why 'perfect' molecules fail during development), and a broad Life Science toolkit covering Process Solutions, Advanced Solutions, Discovery Solutions, and BioReliance® release and stability testing services. Electronics capabilities include semiconductor thin films, optronics, formulations, metrology and inspection, specialty gases, delivery systems, and the Intermolecular® custom innovation brand. These technology assets underpin three distinct revenue streams: subscription/recurring Life Science tools and services, subscription/recurring Healthcare pharmaceutical products, and hardware-based Electronics materials and equipment sales.

Commercially, Merck KGaA runs a global enterprise field-sales model through wholly-owned subsidiary brands (MilliporeSigma, EMD Serono, EMD Electronics) supported by country-specific websites in 65 markets. Pricing is quote-based and not publicly disclosed, consistent with B2B enterprise and specialty pharmaceutical norms. The company is publicly listed on the Frankfurt Stock Exchange (ticker: MRK) and reported €20.2 billion in FY2023 revenue, with FY2025 guidance delivered in Q4 2025 press materials and a €25M BioReliance® testing facility opened in Darmstadt in July 2026. Open-innovation programs (Innovation Cup, Research Grants, Future Insight Prize) support external R&D pipeline development alongside internal Science Space research publication.

Name

默克雪兰诺有限公司

Legal name

Merck KGaA, Darmstadt, Germany

Website

https://merckserono.cn

Company type

Public

Operating status

Operating

Headcount range

101–250 employees

Short description

Merck KGaA, Darmstadt, Germany (Chinese subsidiary: 默克雪兰诺有限公司) is a 1668-founded German science and technology company operating across Life Science (tools/services), Healthcare (pharmaceuticals), and Electronics (semiconductor materials) with 62,000+ employees across 65 countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Life Sciences

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)

akta.pro primary industry

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

akta.pro secondary industries

Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC), Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK), Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG), Manufacturing Quality, GMP Inspections & Compliance (HLAJADAG)

Keywords

• Pharmaceutical products
• Life science tools
• Bioprocessing solutions
• Semiconductor materials
• Specialty chemicals

Headquarters

HQ city

Darmstadt

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Products: Pharmaceutical products including oncology drugs, neurology and immunology treatments, fertility therapies, and general medicine products sold to healthcare providers and patients globally
2. Life Science Tools and Services: Process Solutions, Advanced Solutions, and Discovery Solutions providing tools, services and expertise for researchers and biopharma companies
3. Electronics Materials and Equipment: Semiconductor materials including thin films, specialty gases, formulations, delivery systems, metrology and inspection services for electronics manufacturers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Merck KGaA, Darmstadt, Germany operates through three business units. Life Science (MilliporeSigma) supplies Process Solutions, Advanced Solutions, Discovery Solutions, and BioReliance® biosafety testing services to researchers and biopharmaceutical manufacturers. Healthcare (EMD Serono) develops and commercializes prescription pharmaceuticals in Oncology, Neurology & Immunology, Fertility, and Cardiovascular/Metabolic diseases. Electronics (EMD Electronics) provides high-purity Thin Films, Optronics, Formulations, and Specialty Gases for semiconductor and display manufacturers.

Product overview

Merck KGaA, Darmstadt, Germany operates as a diversified science and technology company with three main business units organized under subsidiary brands. In the United States and Canada, the company uses MilliporeSigma for Life Science, EMD Serono for Healthcare, and EMD Electronics for Electronics. The Life Science business provides Process Solutions, Advanced Solutions, and Discovery Solutions, including BioReliance® testing services. The Healthcare business focuses on Oncology, Neurology & Immunology, Fertility, and Cardiovascular/Metabolism/Endocrinology therapeutic areas, supported by the Vibrant Thoughts blog. The Electronics business offers semiconductor technologies including Thin Films, Optronics, Formulations, Metrology and Inspection, Delivery Systems & Services, Specialty Gases, and the Intermolecular® brand for custom innovation. The company also develops AI-powered tools including Synthia for molecular failure prediction and AIDDISON™ for AI-driven drug design. Research operations include Open Innovation programs (Innovation Cup, Research Grants, Future Insight Prize), AI Research, and Clinical Trials capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• MilliporeSigma: Life science business of Merck KGaA, providing process solutions, advanced solutions, and discovery solutions
• EMD Serono
• EMD Electronics
• EMD (US/Canada umbrella)

Products and services

• Process Solutions (Life Science / MilliporeSigma) Bioprocessing products and services that support biopharmaceutical manufacturing, including filtration, chromatography, raw materials, and process-development tools, sold to biopharma manufacturers and CDMOs.
• Advanced Solutions (Life Science / MilliporeSigma) Products and services supporting cell and gene therapies, gene editing, and advanced biologics development, sold to cell-therapy developers, CDMOs, and research institutions.
• Discovery Solutions (Life Science / MilliporeSigma) Lab consumables, reagents, instruments, and software used by researchers in drug discovery, sold to pharmaceutical companies, academic institutes, and contract research organizations.
• BioReliance® Testing Services Contract biosafety, sterility, viral-clearance, and lot-release testing services for biologics, vaccines, and cell therapies, sold to biopharma manufacturers requiring GMP-compliant testing.
• Oncology Therapeutics (Healthcare / EMD Serono) Prescription drugs used to treat oncological diseases, sold through healthcare providers, hospitals, and specialty pharmacies.
• Neurology & Immunology Therapeutics (Healthcare / EMD Serono) Prescription drugs used to treat neurological and immunological diseases including multiple sclerosis, sold through healthcare providers, hospitals, and specialty pharmacies.
• Fertility Therapeutics (Healthcare / EMD Serono) Drugs and hormone preparations used in assisted reproductive technology and fertility treatment, sold through fertility clinics, hospitals, and specialty pharmacies.
• Cardiovascular and Metabolic Therapeutics (Healthcare / EMD Serono) Prescription drugs for cardiovascular and metabolic diseases, including type 2 diabetes treatments, sold through healthcare providers, hospitals, and pharmacies.
• Thin Films (Electronics / EMD Electronics) High-purity thin-film deposition materials used in semiconductor wafer fabrication and display manufacturing, sold to semiconductor fabs and display panel manufacturers.
• Optronics (Electronics / EMD Electronics) Materials and effects chemicals for optical and optoelectronic applications used in display and lighting manufacturing, sold to display panel makers and specialty OEMs.
• Formulations (Electronics / EMD Electronics) Custom-formulated chemical products for electronics manufacturing, including cleaning, etching, and surface-treatment chemistries, sold to semiconductor and electronics OEMs.
• Specialty Gases (Electronics / EMD Electronics) Ultra-high-purity specialty gases used in semiconductor etching, deposition, and chamber-clean processes, sold to semiconductor fabs and specialty gas distributors.
• AIDDISON™ AI Drug Design Platform Software platform using AI to virtually screen and design small-molecule drug candidates, sold or licensed to pharmaceutical and biotechnology companies to accelerate drug discovery.
• Synthia™ Retrosynthesis AI Software AI-based retrosynthesis planning software that suggests viable synthetic routes for organic molecules, sold or licensed to chemists in pharmaceutical, agrochemical, and specialty chemical companies.

Quantifiable outcome

• €25M BioReliance® facility expansion for biopharma testing services in Europe

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Roche Holding: Large pharmaceutical incumbent with overlapping therapeutic areas (oncology, neurology, immunology) and a diagnostics arm. Comparable as a broad life sciences peer, though Merck's life science tools and electronics businesses are not directly mirrored.
• DuPont de Nemours: Specialty materials company with semiconductor materials, electronics, and healthcare-adjacent offerings. Comparable to Merck's Electronics segment in thin films and electronic materials supply to chipmakers.
• BASF SE: German chemical giant with electronic materials, specialty chemicals, and life science adjacencies. Comparable as a broad German industrial/specialty chemicals incumbent with overlap in electronics materials.
• Novartis AG: Global pharma incumbent with overlapping therapeutic focus areas (neurology, immunology, oncology, cardiovascular). Comparable as a healthcare peer in scale and therapeutic portfolio, though without Merck's life science tools and electronics exposure.
• Sanofi: Diversified global pharmaceutical company with neurology/immunology (Dupixent), rare disease, and vaccines. Comparable on the Healthcare side; less overlap on life science tools and electronics materials.

Emerging players

• Shimadzu Corporation: Japanese analytical and measurement instruments maker (mass spectrometers, chromatography, lab equipment). Comparable to Merck's analytical instruments portfolio within the Life Science business unit.

Direct peers

• Agilent Technologies: Analytical laboratory instruments and life science/chemical analysis provider. Direct competitor to Merck's Discovery Solutions and analytical chemistry offerings across pharma, food, and environmental customers.
• Danaher Corporation: Diversified life science and diagnostics platform (Cytiva, Beckman Coulter, Leica, Pall, IDT). Directly comparable to Merck's Life Science unit across bioprocessing, life science instruments, and biopharma services.
• Lonza Group AG: Global CDMO/biomanufacturing services leader. Direct competitor to Merck's Process Solutions and BioReliance® testing services for biologics manufacturing customers.
• Thermo Fisher Scientific: The closest direct peer to Merck KGaA's Life Science business (MilliporeSigma). Both supply bioprocessing, analytical instruments, lab consumables, and biopharma services (e.g., Patheon/CDMO, PPD) to overlapping biopharma R&D and manufacturing customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/emdgroup
• Facebookfacebook.com/emdgroup
• LinkedInlinkedin.com/company/%E9%BB%98%E5%85%8B%E9%9B%AA%E5%85%B0%E8%AF%BA%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
• Instagraminstagram.com/_emdgroup_/?hl=en

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 默克雪兰诺有限公司